Treats partial-onset seizures. ANDA 78005, held by Ani Pharms. Oxcarbazepine.
As of Nov 16, 2026, ANDA 78005 (Oxcarbazepine), held by Ani Pharms, was first approved by FDA on Dec 11, 2007, with 7 approved supplements and 0 published complete response letters.
Oxcarbazepine Tablets are indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients aged 2 years and above with partial-onset seizures. Oxcarbazepine Tablets are indicated for: Adults: Monotherapy or adjunctive therapy in the treatment of partial-onset seizures Pediatrics Monotherapy in the treatment of partial-onset seizures in children 4 to 16 years Adjunctive therapy in the treatment of partial-onset seizures in children 2 to 16 years
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 11, 2007 | Original application | Approved |
| Oxcarbazepine150MG · tablet;oral | Oxcarbazepine | Rx |
| Oxcarbazepine300MG · tablet;oral | Oxcarbazepine | Rx |
| Oxcarbazepine600MG · tablet;oral | Oxcarbazepine | Rx |
| Jun 8, 2026 | Supplement 12Labeling · Standard review | Approved | None posted |
| Jun 8, 2026 | Supplement 15Labeling · Standard review | Approved | None posted |
| Oct 27, 2020 | Supplement 6Labeling · Standard review | Approved | None posted |
| Oct 27, 2020 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jan 20, 2012 | Supplement 4Manufacturing | Approved | None posted |
| Jun 29, 2010 | Supplement 2Labeling | Approved | None posted |
| Jun 29, 2010 | Supplement 3Labeling | Approved | None posted |
| Dec 11, 2007 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters